Valuation
- Market cap
- 378,086,000
- Revenue TTM
- $0
- Net income TTM
- $-22,230,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,517,300
- Avg volume
- 1,822,668
- Day's range
- $4.49 – $4.77
- Shares out
- 81,660,000
- Stochastic %K
- 22%
- Beta
- 1.45
- Analysts
- Strong Buy
- Price target
- $8.60
Company profile
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It ha...
Show more
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 240 745 6330
- Website
- https://www.i-mabbiopharma.com
- Address
- 2440 Research Boulevard, Suite 400, Rockville, United States
Latest news
No headlines yet.
